Drug Monograph
Adalimumab
Humira and biosimilars (Amjevita, Cyltezo, Hadlima, Hyrimoz, Yuflyma, others)
Pharmacokinetic Profile
Half-Life
~14 days (range 10–20 d)
Bioavailability
64% (SC)
Tmax
5–7 days
Volume of Distribution
4.7–6.0 L (Vss)
Metabolism
Catabolism (proteolysis)
Clinical Information
Drug Class
Anti-TNF-α mAb (biologic DMARD)
Available Doses
10 mg, 20 mg, 40 mg, 80 mg
Route
Subcutaneous
Renal Adjustment
No data; not studied
Hepatic Adjustment
No data; not studied
Pregnancy
Crosses placenta in 3rd trimester; weigh risks
Lactation
Minimal transfer; compatible per experts
Black Box Warning
Yes — Serious Infections & Malignancy
Generic / Biosimilar Available
Yes — multiple biosimilars (some interchangeable)
Adalimumab — Approved Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Rheumatoid arthritis — moderate to severe | Adults | Monotherapy or with MTX / non-biologic DMARDs | FDA Approved |
| Polyarticular juvenile idiopathic arthritis | ≥2 years | Monotherapy or with MTX | FDA Approved |
| Psoriatic arthritis | Adults | Monotherapy or with non-biologic DMARDs | FDA Approved |
| Ankylosing spondylitis | Adults | Monotherapy | FDA Approved |
| Crohn’s disease — moderate to severe | Adults and ≥6 years | Monotherapy or adjunctive | FDA Approved |
| Ulcerative colitis — moderate to severe | Adults and ≥5 years | Monotherapy or adjunctive | FDA Approved |
| Plaque psoriasis — moderate to severe | Adults | Monotherapy | FDA Approved |
| Hidradenitis suppurativa — moderate to severe | ≥12 years | Monotherapy | FDA Approved |
| Non-infectious uveitis (intermediate, posterior, panuveitis) | Adults and ≥2 years | Monotherapy or adjunctive | FDA Approved |
Adalimumab was the first fully human anti-TNF-α monoclonal antibody approved in the United States (December 2002). Its original indication was rheumatoid arthritis, and the label has since expanded to cover nine distinct immune-mediated inflammatory conditions. In RA, adalimumab reduces signs and symptoms, inhibits radiographic progression of joint damage, and improves physical function when used alone or in combination with methotrexate or other conventional DMARDs (FDA PI).
Off-Label Uses
Sarcoidosis — refractory pulmonary, ocular, or cutaneous disease unresponsive to conventional immunosuppressants. Evidence quality: Low (case series, open-label studies).
Pyoderma gangrenosum — steroid-refractory cases. Evidence quality: Low (case reports, small series).
Behcet’s disease — mucocutaneous and ocular involvement refractory to standard therapy. Evidence quality: Moderate (retrospective cohorts, open-label studies).
Adalimumab Dosing by Clinical Scenario
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| RA — with concomitant MTX | 40 mg SC Q2W | 40 mg SC Q2W | 40 mg SC Q2W | Standard first-line biologic dosing for RA; MTX reduces anti-drug antibody formation Concurrent NSAIDs, glucocorticoids, analgesics may continue |
| RA — monotherapy (no MTX) | 40 mg SC Q2W | 40 mg QW or 80 mg Q2W | 80 mg Q2W (or 40 mg QW) | Some patients may benefit from dose escalation if response insufficient Higher immunogenicity without MTX (~12% vs 1% with MTX) |
| Psoriatic arthritis | 40 mg SC Q2W | 40 mg SC Q2W | 40 mg SC Q2W | May use with or without non-biologic DMARDs |
| Ankylosing spondylitis | 40 mg SC Q2W | 40 mg SC Q2W | 40 mg SC Q2W | No loading dose required |
| Crohn’s disease — adult induction/maintenance | 160 mg Day 1, 80 mg Day 15 | 40 mg SC Q2W (from Day 29) | 40 mg SC Q2W | Day 1 dose can be split over 2 consecutive days Weekly dosing is not in the approved label for CD; some clinicians escalate off-label for loss of response |
| Ulcerative colitis — adult | 160 mg Day 1, 80 mg Day 15 | 40 mg SC Q2W (from Day 29) | 40 mg SC Q2W | Discontinue if no remission by Week 8 (Day 57) Pediatric UC has approved weekly options; adult weekly dosing is off-label |
| Plaque psoriasis — adult | 80 mg SC Day 1 | 40 mg SC Q2W (from Week 1) | 40 mg SC Q2W | Close monitoring required; long-term use beyond 1 year not evaluated in controlled trials |
| Hidradenitis suppurativa — adult | 160 mg Day 1, 80 mg Day 15 | 40 mg QW or 80 mg Q2W (from Day 29) | 40 mg QW | Two maintenance regimen options available |
Pediatric Dosing (Weight-Based)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| JIA / Pediatric uveitis — 10 to <15 kg | 10 mg SC Q2W | 10 mg SC Q2W | 10 mg SC Q2W | Ages ≥2 years; may combine with MTX |
| JIA / Pediatric uveitis — 15 to <30 kg | 20 mg SC Q2W | 20 mg SC Q2W | 20 mg SC Q2W | Ages ≥2 years |
| JIA / Pediatric uveitis — ≥30 kg | 40 mg SC Q2W | 40 mg SC Q2W | 40 mg SC Q2W | Same as adult RA dose once weight threshold reached |
Clinical Pearl: Co-administration with Methotrexate
Concomitant MTX substantially reduces formation of anti-adalimumab antibodies (1% with MTX vs ~12% monotherapy in RA trials). The PREMIER trial demonstrated that the combination of adalimumab plus MTX was superior to either agent alone for preventing radiographic progression in early RA. When MTX is not tolerated, other conventional DMARDs such as leflunomide or sulfasalazine may be continued.
Pharmacology
Mechanism of Action
Adalimumab is a fully human recombinant IgG1 monoclonal antibody consisting of 1,330 amino acids with a molecular weight of approximately 148 kDa. It binds with high affinity and specificity to both soluble and membrane-bound tumour necrosis factor-alpha (TNF-α), neutralising its biologic activity by blocking interaction with the p55 (TNFR1) and p75 (TNFR2) cell-surface receptors. Because adalimumab shares an identical framework with naturally occurring human IgG1, it carries lower intrinsic immunogenicity compared with chimeric anti-TNF antibodies. Binding of adalimumab to membrane-associated TNF-α can induce apoptosis of activated inflammatory cells, contributing to downregulation of the inflammatory cascade in the synovium, gut mucosa, and skin. Adalimumab does not bind to or neutralise lymphotoxin (TNF-β) or other cytokines.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ~64% (SC); Tmax 5–7 days; linear pharmacokinetics across 0.5–10 mg/kg IV | Slow absorption allows Q2W dosing; no food effect (parenteral route) |
| Distribution | Vss 4.7–6.0 L; synovial fluid concentrations 31–96% of serum | Good synovial penetration supports efficacy in joint disease; largely confined to vascular and interstitial space |
| Metabolism | Catabolism via proteolytic degradation; not CYP-metabolised; no conventional protein binding studies conducted | No CYP-mediated interactions; however, TNF-α normalisation may restore CYP450 activity (relevant for CYP substrates) |
| Elimination | Clearance ~12 mL/h; terminal t½ ~14 days (range 10–20 d); clearance slightly increases with body weight and is higher in males | Two-week half-life supports Q2W dosing; anti-drug antibodies increase clearance and may reduce efficacy |
Side Effects
Adverse reaction data below are derived from the pooled placebo-controlled RA studies (Studies RA-I through RA-IV; N=705 adalimumab 40 mg Q2W vs N=690 placebo) unless otherwise stated (FDA PI, 2023).
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Injection site reactions (overall, including erythema, pain, swelling) | 20% vs 14% placebo | Mostly mild; rarely necessitate discontinuation; rotation of injection sites may help |
| Upper respiratory infection | 17% vs 13% placebo | Includes common cold and pharyngitis; generally self-limiting |
| Headache | 12% vs 8% placebo | Typically mild to moderate; responds to standard analgesics |
| Rash | 12% vs 6% placebo | Usually non-specific; evaluate for new psoriasiform eruptions (paradoxical psoriasis is a recognised class effect) |
| Sinusitis | 11% vs 9% placebo | Higher incidence reflects general immunosuppression |
| Accidental injury | 10% vs 8% placebo | Includes falls and musculoskeletal trauma |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 9% vs 8% placebo | Usually transient; consider peri-injection timing |
| Injection site reaction (excl. erythema/pain/swelling) | 8% vs 1% placebo | Specific reactions such as induration or haemorrhage at injection site |
| Urinary tract infection | 8% vs 5% placebo | Monitor for recurrent UTIs; treat promptly |
| Laboratory test abnormal | 8% vs 7% placebo | Includes liver enzyme elevations (ALT ≥3× ULN in 3.5% of RA/PsA/AS patients) |
| Abdominal pain | 7% vs 4% placebo | Evaluate for GI infections in immunosuppressed patients |
| Flu syndrome | 7% vs 6% placebo | Includes myalgia, fatigue, and malaise |
| Hyperlipidemia | 7% vs 5% placebo | Monitor lipid profile; may reflect disease control or independent effect |
| Hypercholesterolemia | 6% vs 4% placebo | Related finding; baseline and periodic lipid monitoring advisable |
| Back pain | 6% vs 4% placebo | May be difficult to distinguish from underlying RA symptoms |
| Hypertension | 5% vs 3% placebo | Monitor blood pressure periodically |
| Hematuria | 5% vs 4% placebo | Investigate persistent hematuria to exclude other causes |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Serious infections (pneumonia, sepsis, cellulitis, opportunistic) | 4.3 per 100 PY vs 2.9 placebo | Any time during treatment | Discontinue adalimumab; initiate antimicrobial treatment; do not restart until infection fully resolved |
| Tuberculosis (active or reactivation) | 0.27 per 100 PY | Months to years; often within first year | Screen before and during therapy; treat latent TB before starting; discontinue if active TB develops |
| Invasive fungal infections (histoplasmosis, coccidioidomycosis) | Rare | Variable; consider in endemic regions | Consider empiric antifungal therapy in febrile patients from endemic areas; stop adalimumab |
| Lymphoma | ~0.11 per 100 PY (SIR 3.19) | Years; long-term exposure | Evaluate unexplained lymphadenopathy or B symptoms; discontinue and refer to oncology |
| Hepatosplenic T-cell lymphoma (HSTCL) | Very rare | Months to years; mainly IBD patients on thiopurines | Almost universally fatal; highest risk in young males on combination immunosuppression |
| Demyelinating disease (new-onset or exacerbation) | Rare (post-marketing) | Weeks to months | Discontinue adalimumab; refer to neurology; do not use in patients with pre-existing MS |
| Congestive heart failure (new onset or worsening) | Rare | Weeks to months | Exercise caution in NYHA class III/IV; discontinue if CHF worsens |
| Lupus-like syndrome | Rare (2/3046 in RA trials) | Months of treatment | Discontinue; syndrome typically resolves after stopping therapy |
| Hepatitis B reactivation | Rare (HBV carriers at risk) | During treatment or months after stopping | Screen all patients before initiation; monitor carriers closely; stop adalimumab and start antiviral if reactivation occurs |
| Anaphylaxis / severe hypersensitivity | Very rare (post-marketing) | Minutes to hours post-injection | Emergency treatment; permanent discontinuation |
| Cytopenias / pancytopenia | Rare | Variable | Obtain urgent CBC if signs of infection, bruising, or pallor; consider discontinuation |
Discontinuation
Discontinuation Rates
Adults (RA Trials)
7% vs 4% placebo
Top reasons: Clinical flare (0.7%), rash (0.3%), pneumonia (0.3%)
Pediatric (JIA)
~6%
Top reasons: Hypersensitivity reactions, infections (serious infections in ~4–9%)
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Clinical flare reaction | 0.7% | Most common reason in pooled RA studies (RA-I through RA-IV) |
| Rash | 0.3% | Evaluate for paradoxical psoriasis before attributing to adalimumab |
| Pneumonia | 0.3% | Immunosuppression-related; requires clinical assessment |
Management: Injection Site Reactions
Injection site reactions are the single most common complaint with adalimumab but rarely warrant discontinuation. Practical strategies include allowing the prefilled syringe or pen to reach room temperature (15–30 minutes) before injection, rotating injection sites between the abdomen and thigh, and applying ice to the area briefly before injection. Patients should avoid injecting into skin that is tender, bruised, red, or hard.
Drug Interactions
Adalimumab is not metabolised by cytochrome P450 enzymes and has no conventional pharmacokinetic drug interactions. However, TNF-α suppression can normalise elevated CYP450 activity seen in chronic inflammation, potentially altering levels of narrow-therapeutic-index CYP substrates. The most clinically significant interactions are pharmacodynamic and relate to additive immunosuppression.
Major
Anakinra (IL-1 receptor antagonist)
MechanismAdditive immunosuppression via dual cytokine blockade
EffectSignificantly increased risk of serious infections without improved clinical benefit in RA
ManagementCombination is contraindicated per FDA labeling; do not co-prescribe
FDA PI
Major
Abatacept (T-cell co-stimulation blocker)
MechanismAdditive immunosuppression from dual biologic mechanism
EffectGreater proportion of serious infections vs TNF blocker alone, with no added efficacy
ManagementCombination not recommended; allow adequate washout when switching between biologics
FDA PI
Major
Live vaccines
MechanismTNF-α blockade may compromise immune response to live pathogens
EffectRisk of disseminated infection from live vaccine organisms; unknown safety in in-utero-exposed infants
ManagementAvoid live vaccines during adalimumab therapy; bring vaccinations up to date before initiating treatment; inactivated vaccines may be given concurrently
FDA PI
Major
Other biologic DMARDs (e.g., rituximab, tocilizumab)
MechanismOverlapping immunosuppressive pathways
EffectElevated risk of opportunistic infections without demonstrated additional benefit
ManagementDo not combine biologic DMARDs; allow washout period when switching (varies by agent half-life)
ACR Guidelines
Moderate
Azathioprine / 6-Mercaptopurine
MechanismAdditive immunosuppression; possible link to HSTCL in young IBD patients
EffectPost-marketing reports of fatal hepatosplenic T-cell lymphoma, primarily in adolescent/young adult males with IBD
ManagementWeigh risks vs benefits carefully, especially in young IBD patients; consider monotherapy alternatives when feasible
FDA PI / Post-Marketing
Moderate
CYP450 substrates with narrow therapeutic index (e.g., warfarin, theophylline, ciclosporin)
MechanismTNF-α normalisation restores suppressed CYP450 activity, potentially lowering drug levels
EffectPossible decrease in serum concentrations of CYP substrates upon starting adalimumab
ManagementMonitor levels of narrow-TI drugs (e.g., INR for warfarin) when initiating or discontinuing adalimumab; dose adjustments may be needed
FDA PI
Minor
Methotrexate
MechanismMTX reduces adalimumab clearance by approximately 29–44%, likely by suppressing anti-drug antibody formation
EffectHigher adalimumab trough levels and improved efficacy; beneficial interaction
ManagementNo dose adjustment of either agent needed; co-administration is the recommended strategy in RA
FDA PI
Minor
Inactivated vaccines
MechanismImmunosuppression may reduce vaccine immunogenicity
EffectProtective antibody responses to pneumococcal and influenza vaccines maintained; influenza titres may be modestly lower
ManagementMay administer concurrently; preferably vaccinate before starting adalimumab if possible
FDA PIMonitoring
-
TB Screening
Before initiation; periodically during therapy
Routine TST or IGRA before starting treatment. Repeat at least annually for patients with ongoing TB risk factors (travel, occupational exposure). Treat latent TB before initiating adalimumab. Monitor for signs of active TB throughout treatment, even if initial test negative. -
Hepatitis B
Before initiation; during and after therapy in carriers
Routine Screen all patients for HBV (HBsAg, anti-HBc, anti-HBs) before starting. HBV carriers require clinical and laboratory monitoring (HBV DNA, ALT) throughout treatment and for several months after stopping. -
CBC with Differential
Baseline; then periodically
Routine Monitor for cytopenias and pancytopenia. Urgently check if patient presents with persistent fever, bruising, bleeding, or pallor. -
Liver Function Tests
Baseline; periodically
Routine ALT elevations ≥3× ULN occurred in 3.5% of RA/PsA/AS patients (vs 1.5% placebo). More frequent with concurrent MTX. Evaluate patients with jaundice or marked enzyme rises. -
Signs of Infection
Every visit
Routine Assess for fever, cough, weight loss, night sweats, or any new focal symptoms at each clinical encounter. Serious infection rate is 4.3 per 100 patient-years. -
Skin Examination
Annually; more often if risk factors
Routine Non-melanoma skin cancer incidence is raised in RA/Ps patients on TNF blockers. Perform periodic skin examination, especially in those with prior skin malignancy or extensive UV exposure. -
Heart Failure Symptoms
If pre-existing CHF
Trigger-Based Assess for worsening dyspnoea, oedema, or weight gain in patients with heart failure. Discontinue if CHF worsens. -
Neurological Symptoms
If new symptoms arise
Trigger-Based Evaluate new-onset visual disturbance, limb weakness, numbness, or paraesthesia promptly. Consider demyelinating disease and neurology referral. -
ANA / Anti-dsDNA
If lupus-like symptoms develop
Trigger-Based 12% of RA patients with negative baseline ANA seroconverted at Week 24. Clinically significant lupus-like syndrome is rare (2/3046 in trials) but warrants discontinuation.
Contraindications & Cautions
Absolute Contraindications
- Active serious infection — including active TB, sepsis, or opportunistic infections. Do not initiate until the infection is fully controlled.
- Active hepatitis B infection — initiation is contraindicated in active HBV; carriers require prophylaxis and close monitoring if treated.
Relative Contraindications (Specialist Input Recommended)
- Pre-existing demyelinating disease (e.g., multiple sclerosis, optic neuritis) — TNF blockade has been associated with new onset or exacerbation of demyelinating disorders; specialist neurology input is essential before prescribing.
- Moderate to severe heart failure (NYHA Class III/IV) — higher-dose TNF blockade has been associated with worsening CHF in trials of other agents; exercise caution and monitor closely.
- History of lymphoma or other malignancy — risk-benefit evaluation required; long-term TNF blockade may increase malignancy risk, though data are confounded by underlying disease risk.
- Chronic or recurrent infection — documented risk-benefit discussion with the patient is required; close monitoring is mandatory.
Use with Caution
- Elderly patients (≥65 years) — greater risk of serious infections; no dose adjustment recommended but heightened vigilance warranted.
- Latent TB (treated) — reactivation can occur despite prophylaxis; maintain TB surveillance throughout treatment.
- HBV carriers — monitor for reactivation during and for several months after stopping; initiate antiviral therapy if reactivation occurs.
- Concurrent immunosuppressants — combination with MTX or corticosteroids increases infection risk; use the lowest effective doses.
- Pregnancy — adalimumab crosses the placenta, particularly in the third trimester. A pregnancy registry found major birth defect rates of 10% (vs 7.5% unexposed), though no specific pattern was identified. Live vaccines should be avoided in infants exposed in utero for at least 5 months after the mother’s last dose.
FDA Boxed Warning
Serious Infections and Malignancy
Serious Infections: Patients treated with adalimumab are at increased risk for developing serious infections that may lead to hospitalisation or death. These include tuberculosis (active or reactivation of latent disease), invasive fungal infections (histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis), and bacterial, viral, and other opportunistic infections. Adalimumab should be discontinued if a patient develops a serious infection or sepsis.
Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have occurred in adolescent and young adult patients with inflammatory bowel disease treated with TNF blockers, particularly in combination with azathioprine or 6-mercaptopurine.
Patient Counselling
Purpose of Therapy
Adalimumab works by blocking a protein called TNF-alpha that drives inflammation in conditions like rheumatoid arthritis. By reducing this inflammation, it helps to relieve joint pain, stiffness, and swelling, slow the progression of joint damage, and improve daily function. It does not cure the underlying condition but can bring about significant and sustained improvement in many patients.
How to Take
Adalimumab is given as an injection under the skin (subcutaneous), typically every two weeks. Patients can be trained to self-inject using a prefilled pen or syringe. The injection should be given in the thigh or lower abdomen (avoiding within 2 inches of the navel), rotating sites each time. Allow the pen or syringe to sit at room temperature for 15–30 minutes before injecting. If a dose is missed, inject as soon as possible and then resume the regular schedule.
Injection Site Reactions
Tell patient
Mild redness, pain, itching, or swelling at the injection site is common (affects up to 1 in 5 patients) and usually improves with continued use. Letting the medication reach room temperature before injection and rotating sites can reduce discomfort.
Call prescriber
If injection site reactions are severe, spreading, or associated with significant swelling, warmth, or drainage suggestive of infection.
Infection Risk
Tell patient
Adalimumab lowers the immune system’s ability to fight infections. Minor infections like colds are common. Practice good hand hygiene, avoid close contact with people who are unwell, and stay up to date with recommended (non-live) vaccinations.
Call prescriber
If you develop a fever, persistent cough, night sweats, unexplained weight loss, painful or frequent urination, or any signs of infection that do not resolve quickly. Seek urgent care for high fever or signs of sepsis.
Cancer Awareness
Tell patient
There is a small increased risk of certain cancers, including lymphoma and skin cancers, with long-term use of TNF blockers. Attend regular skin checks and report any new lumps, unexplained weight loss, or persistent swollen glands.
Call prescriber
If you notice new skin lesions, non-healing sores, unexplained bruising, persistent fatigue, or swollen lymph nodes.
Neurological Symptoms
Tell patient
In rare cases, adalimumab can affect the nervous system. This is uncommon but requires prompt evaluation.
Call prescriber
If you experience new numbness, tingling, vision changes, or weakness in your arms or legs.
Heart Failure Symptoms
Tell patient
If you have heart failure, adalimumab may occasionally make symptoms worse. Monitor your weight daily and note any changes in breathing or ankle swelling.
Call prescriber
If you experience new or worsening shortness of breath, sudden weight gain, or ankle/foot swelling.
Storage and Handling
Tell patient
Store adalimumab in the refrigerator (2–8°C). Do not freeze. Protect from light. The medication is preservative-free; discard any unused portion after opening. Check the expiry date before each injection.
Call prescriber
If the solution appears cloudy, discoloured, or contains particles — do not use.
Sources
Regulatory (PI / SmPC)
- AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use. Full Prescribing Information. Revised 11/2023. FDA Label Primary source for all dosing, indications, boxed warnings, adverse reaction incidence rates, and pharmacokinetic data.
- AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use. Full Prescribing Information. Revised 2025. FDA Label (2025 revision) Most recent FDA label revision; confirms consistency of safety and dosing recommendations.
- European Medicines Agency. Humira — EPAR Scientific Discussion. EMA EMA regulatory review providing pharmacokinetic modelling data and European clinical trial outcomes.
Key Clinical Trials
- Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37. doi:10.1002/art.21519 Landmark trial demonstrating superiority of adalimumab + MTX over either monotherapy in early RA.
- Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400-1411. doi:10.1002/art.20217 Study RA-III (ARMADA extension); established efficacy for inhibiting radiographic progression with adalimumab + MTX.
- Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45. doi:10.1002/art.10697 Pivotal phase III trial demonstrating ACR20/50/70 responses in MTX-inadequate responders.
Guidelines
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939. doi:10.1002/acr.24596 Current ACR guideline positioning TNF inhibitors including adalimumab as preferred biologics after csDMARD inadequate response.
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356 EULAR consensus on biologic DMARD sequencing in RA, including TNF-inhibitor positioning.
Mechanistic / Basic Science
- Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279. doi:10.1016/j.pharmthera.2007.10.001 Comprehensive review of TNF-α biology and mechanisms by which TNF blockers exert anti-inflammatory effects.
Pharmacokinetics / Special Populations
- Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286-297. doi:10.1111/bcp.12509 Population PK study in RA characterising influence of body weight, sex, and anti-drug antibodies on adalimumab clearance.
- Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517-524. doi:10.1136/annrheumdis-2011-201244 Largest long-term safety analysis of adalimumab across six indications; source for serious infection and malignancy rates.
- Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889-894. doi:10.1136/ard.2005.043166 Early post-marketing safety review providing standardised incidence ratios for lymphoma and infection rates in RA patients.
- Adalimumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. NCBI Bookshelf Peer-reviewed clinical pharmacology overview covering all approved indications, dosing, and adverse effects.